Two clinical trials with antibodies targeting alpha synuclein in early Parkinson’s disease have been published in the New England Journal of Medicine. Anthony Lang and Gennaro Pagano, the first authors of the articles share the results and discuss the possible future perspectives with the MDS Podcast editor, Michele Matarazzo. Read the prasinezumab article. Read the…
Read MoreIn part 5 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Jill Ostrem about current and future approaches to treatment of dystonia.
Read MoreIn part 4 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Anna Sadnicka on the neural roots of dystonia.
Read MoreDr. Matarazzo interviews Émeline Courtois about the recently published article on machine learning approach to discover marketed drugs that could have an impact on the development of Parkinson’s disease. Interestingly, furosemide and adrenergic drugs showed a potential protective effect in this very large cohort. Journal CME is available until January 19, 2024 Read the article.
Read MoreIn part 3 of the Dystonia Special Series, Dr. Francesca Morgante interviews Prof. Carolyn Sue on the Genetic landscape of dystonia.
Read MoreClozapine is a antipsychotic drug that has been marketed for decades. In this interview, Dr. Friedman shares his thoughts on its utility in Parkinson’s disease along with some practical advices on how to use it in the clinic. Read the article.
Read MoreIn part 2 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Davide Martino on the non-motor features of dystonia.
Read MoreSara Schaefer speaks to Alan Whone of the University of Bristol on his retrospective analysis of off-state dyskinesias in Parkinson’s disease patients who received serial infusions of GDNF into the putamen. Read the article.
Read MoreIn part 1 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Miryam Carecchio on pearls on diagnosis and phenomenology of dystonic syndrome.
Read MoreProf Martino points out the existent literature concerning the objective findings in the 3 cardinal domains of idiopathic normal pressure hydrocephalus. Read the article.
Read More